CEL-SCI files Breakthrough Medicine Designation with Saudi FDA for Multikine; signs MOU with Dallah Pharma

CEL SCI CORP

Breakthrough Medicine Designation application filed with SFDA by Dallah Pharma for Multikine.
MOU signed with Dallah Pharma for commercialization; final partnership expected Q3 2025.
SFDA response time ~60 days; if granted, Multikine available for patient access and reimbursement in Saudi Arabia.
Dallah Healthcare serves over 3 million patients annually via network of hospitals and clinics.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.